VIRxSYS (www.virxsys.com) is developing a unique technology that is advancing both gene therapy and HIV treatment. VRX496 uses a lentiviral vector to deliver a payload to block the replication of HIV.

Wacker Biotech US, a CDMO, and Expression Manufacturing, which specializes in viral vector technology, agreed to collaborate to advance the development and manufacturing of lentiviral-based gene and ...

As a lab within the Cooperative Center of Excellence in Hematology (CCEH) at Fred Hutch, the Vector Production core assists investigators with the design, construction, and/or production of viral ...

The expansion of LENTIVERSE™ platform introduces "One Lentiviral Vector Platform, Two Paths to Advance Cures," aligning scientific rigor with transparent economics and global accessibility.

Acquired from the human immunodeficiency virus (HIV), lentiviral vectors are one of the most practical and commonly used viral vectors. They provide the ability to transduce both non-dividing and ...

Lentiviruses have the unique ability amongst retroviruses of being able to infect non-cycling cells. Vectors derived from lentiviruses have provided a huge advancement in technology and seemingly ...

The global lentiviral vector CDMO market is set to witness a growth rate of 8% in the next 5 years. Growing demand for gene and cell therapies; expanding pipeline of gene therapy products; ...

Lentivirus is a genus in the family of Retroviridae that is very suitable for remodeling into gene transfer vectors due to its stable transgene expression, the ability to reach the nuclei of the ...